This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nevin, D. N. Articles by Brunzell, J. D. Search for Related Content PubMed PubMed Citation Articles by Nevin, D. N. Articles by Brunzell, J. D. Pubmed/NCBI databases Substance via MeSH Genetics Home Reference

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16:1243-1249.)
© 1996 American Heart Association, Inc.

Articles

Paraoxonase Genotypes, Lipoprotein Lipase Activity, and HDL

David N. Nevin; Alberto Zambon; Clement E. Furlong; Rebecca J. Richter; Richard Humbert; John E. Hokanson; John D. Brunzell

the Divisions of Metabolism, Endocrinology, and Nutrition (D.N.N., A.Z., J.E.H., J.D.B.), and Medical Genetics (C.E.F., R.J.R., R.H.), Department of Medicine, School of Medicine, and the Department of Epidemiology, School of Public Health and Community Medicine (J.E.H.), University of Washington.

Correspondence to John D. Brunzell, MD, University of Washington, Endocrinology/Metabolism, Box 356426, Seattle, WA 98195-6426. E-mail brunzell@u.washington.edu.

Paraoxonase, an enzyme associated with the high density lipoprotein (HDL) particle, hydrolyzes paraoxon, the active metabolite of the insecticide parathion. Several studies have shown that paraoxonase levels in humans have a distribution characteristic of two alleles, one with low activity and the other with high activity. Paraoxonase also has arylesterase activity, which does not exhibit activity polymorphism and can therefore serve as an estimate of enzyme protein. Although the ability of paraoxon to irreversibly inhibit lipoprotein lipase (LPL) has been exploited experimentally for many years, the role of plasma paraoxonase in lipoprotein metabolism is unknown. Seventy-two normal individuals were examined for paraoxonase genotypes, plasma paraoxonase and arylesterase activities, postheparin LPL and hepatic lipase (HL) activities, and lipoprotein levels to determine whether (1) paraoxonase activity or genotype determines lipoprotein levels via an effect on LPL or HL activity or (2) variation in LPL and HL activities determines HDL levels and indirectly affects paraoxonase activity and protein levels in plasma. In the entire group, paraoxonase activity was related to arylesterase activity and genotype. Whereas arylesterase activity was correlated with HDL cholesterol (HDL-C) and apolipoproteinA-I (apoA-I) levels, neither arylesterase nor paraoxonase was correlated with LPL or HL activity. Furthermore, LPL activity was positively correlated and HL inversely correlated with HDL cholesterol and apoA-I levels, whereas LPL was inversely correlated with triglyceride levels. The paraoxonase genotypes of the study group were 30 individuals homozygous for the low-activity allele, 38 heterozygotes, and 4 individuals homozygous for the high-activity allele. Paraoxonase genotype accounted for .75 of the variation in paraoxonase activity. Paraoxonase activity was linearly related to arylesterase activity within each subgroup. No difference in either LPL or HL activity was seen as a function of paraoxonase genotype, nor were differences seen in plasma triglyceride or HDL-C by genotype by ANOVA. The relation between LPL and HL and components of HDL in the paraoxonase genotypic subgroups in general reflected the associations seen in the group as a whole. Multivariate analysis showed that LPL, HL, and arylesterase, a measure of paraoxonase mass, were independent predictors of HDL cholesterol, while paraoxonase genotype or activity was not. Thus, variation in LPL and HL appears to be significantly related to HDL cholesterol and apoA-I levels. The levels of HDL are a major correlate of paraoxonase protein levels, while paraoxonase genotype is the major predictor of plasma paraoxonase activity.

Key Words: arylesterase • paraoxon • hepatic lipase • apolipoproteinA-I • apolipoproteinA-II

This article has been cited by other articles:

				F. Marchegiani, M. Marra, L. Spazzafumo, R. W. James, M. Boemi, F. Olivieri, M. Cardelli, L. Cavallone, A. R. Bonfigli, and C. Franceschi Paraoxonase activity and genotype predispose to successful aging. J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 541 - 546. [Abstract] [Full Text] [PDF]

				L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895. [Abstract] [Full Text] [PDF]

				N. Ferre, J. Camps, J. Fernandez-Ballart, V. Arija, M. M. Murphy, S. Ceruelo, E. Biarnes, E. Vilella, M. Tous, and J. Joven Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General Population Clin. Chem., September 1, 2003; 49(9): 1491 - 1497. [Abstract] [Full Text] [PDF]

				M. C. Cheung, S. D. Sibley, J. P. Palmer, J. F. Oram, and J. D. Brunzell Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I,A-II) J. Lipid Res., August 1, 2003; 44(8): 1552 - 1558. [Abstract] [Full Text] [PDF]

				G. P. Jarvik, T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1465 - 1471. [Abstract] [Full Text] [PDF]

				G. P. Jarvik, L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype Arterioscler Thromb Vasc Biol, November 1, 2000; 20(11): 2441 - 2447. [Abstract] [Full Text] [PDF]

				B. J. Kudchodkar, A. G. Lacko, L. Dory, and T. V. Fungwe Dietary Fat Modulates Serum Paraoxonase 1 Activity in Rats J. Nutr., October 1, 2000; 130(10): 2427 - 2433. [Abstract] [Full Text]

				S. Sen-Banerjee, X. Siles, and H. Campos Tobacco Smoking Modifies Association Between Gln-Arg192 Polymorphism of Human Paraoxonase Gene and Risk of Myocardial Infarction Arterioscler Thromb Vasc Biol, September 1, 2000; 20(9): 2120 - 2126. [Abstract] [Full Text] [PDF]

				H. Cao, A. Girard-Globa, F. Berthezene, and P. Moulin Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q->R genetic polymorphism J. Lipid Res., January 1, 1999; 40(1): 133 - 139. [Abstract] [Full Text]

				T. Zama, M. Murata, Y. Matsubara, K. Kawano, N. Aoki, H. Yoshino, G. Watanabe, K. Ishikawa, and Y. Ikeda A 192Arg Variant of the Human Paraoxonase (HUMPONA) Gene Polymorphism Is Associated With an Increased Risk for Coronary Artery Disease in the Japanese Arterioscler Thromb Vasc Biol, December 1, 1997; 17(12): 3565 - 3569. [Abstract] [Full Text]